Navigation Links
Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
Date:9/6/2011

00.89&rank=1">http://clinicaltrials.gov/ct2/show/NCT01325428?term=afatinib+1200.89&rank=1.  U.S. investigators who are interested in becoming involved in this study and have potentially eligible patients should contact Boehringer Ingelheim at: clintriage.rdg@boehringer-ingelheim.com.  

About Afatinib

Afatinib is an investigational compound.  Afatinib is not approved by the FDA; its safety and efficacy have not been established.  

Afatinib is an orally-administered irreversible inhibitor of the erbB family of receptor tyrosine kinases, specifically EGFR and HER2.  In addition to breast cancer, afatinib is also in late-stage clinical development in NSCLC, the most common type of lung cancer. LUX-Lung 3 is a phase III study in patients with NSCLC and EGFR mutations, which compares single-agent afatinib with chemotherapy using cisplatin/pemetrexed as first-line treatment.

About Boehringer Ingelheim in Oncology

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim is committed to discovering and developing novel cancer treatments. This commitment is underpinned by using advances in science to develop a range of targeted therapies in areas of medical need, including seven investigational compounds in different phases of development for solid tumors and hematological cancers.

The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition.  Afatinib is currently in phase III clinic
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  MedScope ( www.medscope.org ), the ... for a 2015 Connected World magazine Connected ... System (mPERS), that can be used anywhere, anytime. The ... In nominating MedScope, Landon Garner ...
(Date:1/23/2015)... NEW YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer ... the board of directors of Advaxis, Inc. ("Advaxis" or ... the board has breached its fiduciary duties to shareholders. ... published on an investing website reporting that Advaxis had ...
(Date:1/23/2015)... 2015  Now available for sale, The Armor1 Ankle Roll ... ankle sprains by cushioning the ankle from an inversion ... the outside of any shoe type and allows the ... offering protection against sprains. With customers in physical therapy, ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2
... of the world,s leading research and advisory firms for pharmaceutical ... grow from $246 million in 2009 to $403 million in ... to the Emerging Markets report entitled Asthma in ... access to medical care, a growing drug-treated population and a ...
... 2010 Royal Philips Electronics (NYSE: PHG, AEX: PHI) ... international analysis on issues and challenges facing home healthcare. ... reliance on home healthcare is necessary to better equip ... population living longer with chronic illnesses. ...
Cached Medicine Technology:India's Asthma Drug Market Will Exceed $400 Million in 2014 2Philips-Commissioned RAND Report Highlights Promise of Home Health and Need for Multi-Stakeholder Action to Break Down Barriers to Adoption 2Philips-Commissioned RAND Report Highlights Promise of Home Health and Need for Multi-Stakeholder Action to Break Down Barriers to Adoption 3
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... January 23, 2015 Recently, Weddingshe.com has added ... and has announced its highest annual revenues in the past ... its popular glamorous wedding dresses. , According to the sales ... wedding dress promotions for them in 2015. This point can ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Four years since the ... – which coincided with the marriage of Avasa & Matthew Love ... ROAD, which is scheduled for release through White Swan Records on ... that there is a sacred path available to all of us ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
(Date:1/22/2015)... 2015 JJsHouse.com is a famous dress online ... business announces its latest collection of wedding dresses , ... important issue is the wedding dress on your big day; ... woman’s life. Every bride wants to find the most suitable ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... molecular mechanism behind the aggressive head and neck cancer was ... Center (SFVAMC). // It is a highly malignant form ... discovered the triple interaction between CD44, hyaluronan (HA), and LARG. ... role in a variety of cellular functions. Hyaluronan (HA) is ...
... a negative impact on the kids. Researchers from the ... Boston studied the effect of obese kids watching television. ... Pediatric and Adolescent Medicine. ,Jean Wiecha ... overweight as kids tend to eat the foods that ...
... disease that kills about 60,000 people annually. It spreads ... Visceral leishmaniasis infects about 500,000 people annually mainly in ... drugs to treat leishmaniasis have serious side effects and ... loss, and abnormalities of the liver and spleen. As ...
... been done by an Australian team of scientists who have ... a molecule //that is 100 times more effective against bacteria ... This could be the answer for super drugs with antibiotic ... of New Scientist.,Research director in animal genetics and genomics for ...
... of Medicine is launching an initiative to assess if ... the number of hospitalizations in heart failure patients.// Tele-HF ... funded by the National Heart, Lung and Blood Institute. ... patients across the country. Patients from the 15 community-based ...
... National Highway Traffic Safety Administration and the Virginia Tech ... phones //or apply makeup while they drive are thrice ... focus on driving. ,Researchers studied 241 drivers ... crashes and 761 near-crashes, according to CNN. The research ...
Cached Medicine News:Health News:A Detail Analysis of Head and Neck Cancer 2Health News:Effective Vaccine for Leishmaniasis in the Pipeline 2
Herpes Simplex Virus 2 IgG ELISA....
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of small sized foreign bodies....
Blunt tipped forceps with long thin tips (3 mm) angled at approximately 120. For grasping of subretinal membranes. Color Coding: Gold....
Microforceps: Claes ILM Forceps...
Medicine Products: